Gilead Sciences (GILD) Cash & Equivalents Growth (5y) (2014 - 2026)

Gilead Sciences (GILD) Cash & Equivalents Growth (5y) (2014 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 13.41%
Dec 31, 2025 4.75%
Sep 30, 2025 -10.67%
Jun 30, 2025 -5.28%
Mar 31, 2025 -4.64%
Dec 31, 2024 -2.99%
Sep 30, 2024 -11.87%
Jun 30, 2024 -24.42%
Mar 31, 2024 -22.55%
Dec 31, 2023 -19.45%
Sep 30, 2023 -17.10%
Jun 30, 2023 -15.49%
Mar 31, 2023 -8.37%
Dec 31, 2022 -6.54%
Sep 30, 2022 -16.40%
Jun 30, 2022 -11.47%
Mar 31, 2022 -16.02%
Dec 31, 2021 -8.29%
Sep 30, 2021 -14.96%
Jun 30, 2021 -5.48%